Tandem Diabetes Care (Nasdaq:TNDM) filed an SEC Form 8-K announcing its chief commercial officer’s intent to resign. Brian B. Hansen, EVP and CCO, notified the company of his decision to resign on Aug. 17. His resignation goes into effect on Dec. 31, 2023. In connection with Hansen’s resignation, he and the automated insulin delivery technology […]
Tandem Diabetes Care
Tandem provides pathway to transition to new insulin pump platform
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it made a new, limited-time offer for its Tandem Choice technology access program. The San Diego-based company’s program provides new and renewing, eligible users of its insulin pump a pathway to its new offerings. Users of the t:slim X2 insulin pump in the U.S. can use the program […]
Tandem resets 2023 guidance due to reduced sales visibility from new product disruption
Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit on second-quarter results that included amended full-year financial guidance. Changes to the automated insulin delivery technology maker’s outlook reflect updates to its portfolio and reduced visibility on sales for the near future. Shares of TNDM fell 15% to $27.19 apiece after the market closed today. MassDevice’s MedTech 100 Index — […]
8 drug delivery innovations you should know
Innovations in drug delivery never stop, and over the past 12 months or so a wide variety have been in the spotlight. Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing the many ways we can […]
FDA clears Tandem Diabetes Care’s Mobi durable automated insulin pump
Tandem Diabetes Care (Nasdaq:TNDM) announced today that the FDA cleared its Tandem Mobi automated insulin delivery (AID) system. Clearance covers people with diabetes ages six and up, expanding the Tandem portfolio of products. San Diego-based Tandem says Mobi, which is fully controllable from a mobile app, is the world’s smallest durable AID system. Mobi features […]
Tandem stock dips after hours on Q1 misses as it teases 2023 product launches
Tandem Diabetes Care (Nasdaq:TNDM) shares ticked down after hours today on first-quarter results that fell shy of the consensus forecast. Shares of TNDM fell 9.9% to $36 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.3%. The […]
Tandem reports positive research for its artificial pancreas tech
Tandem Diabetes Care (Nasdaq:TNDM) today announced a positive meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. The research found immediate and sustained improvements for a diverse range of subjects using Control-IQ technology, according to the research published in the journal Diabetes Technology & Therapeutics. There was an average increase in […]
Study backs Tandem Control-IQ artificial pancreas in young children
Tandem Diabetes Care (Nasdaq:TNDM) announced positive study data for its artificial pancreas using Control-IQ technology. The study demonstrated improved blood sugar control in children ages 2-6 with type 1 diabetes. It evaluated an artificial pancreas using the Tandem t:slim x2 insulin pump with Control-IQ technology. Results were published in the New England Journal of Medicine. […]
Tandem Diabetes Care appoints new board chair
Tandem Diabetes Care (Nasdaq:TNDM) recently announced the appointment of Rebecca Robertson as the chair of its board of directors. Robertson initially joined Tandem’s board as an independent director in January 2019. She succeeds Kim Blickenstaff as chair. Blickenstaff intends to continue as a member of the board. Get the full story at our sister site, […]
Tandem Diabetes Care stock down on Q4 misses
Tandem Diabetes Care (Nasdaq:TNDM) shares are down today on fourth-quarter results that came up shy of the consensus forecast. Shares of TNDM were down more than 6% to $37.28 apiece by midday trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 8%. Yesterday evening, the […]
The year ahead in diabetes care: what to expect in 2023
After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]
